In vitro neutralization capacity of purified JWW-1 and JWW-2 monoclonal antibodiesa
| HPV luciferase reporter | Monoclonal antibody | IC50 (95% CI) (nM) |
|---|---|---|
| HPV6 | RG-1 | >200 (NA) |
| JWW-1 | >200 (NA) | |
| JWW-2 | 160 (22–1,192) | |
| Human IgG control | >200 (NA) | |
| HPV16 | RG-1 | <0.27 (NA) |
| JWW-1 | 0.4 (0.2–0.88) | |
| JWW-2 | 4.8 (3.3–6.9) | |
| Human IgG control | >200 (NA) | |
| HPV26 | RG-1 | 3.2 (2.1–4.9) |
| JWW-1 | <0.27 (NA) | |
| JWW-2 | >200 (NA) | |
| Human IgG control | >200 (NA) | |
| HPV45 | RG-1 | >200 (NA) |
| JWW-1 | 6.6 (2.3–19) | |
| JWW-2 | 71 (5.2–980) | |
| Human IgG control | >200 (NA) | |
| HPV58 | RG-1 | >200 (NA) |
| JWW-1 | 67 (10–510) | |
| JWW-2 | 75 (12–480) | |
| Rat IgG control | >200 (NA) |
↵a Shown is a summary of the 50% inhibitory concentration (IC50) (95% confidence interval [CI]) of purified monoclonal antibodies RG-1, JWW-1, JWW-2, and a negative-control human IgG determined using the FC-PBNA against HPV6/16/26/45/58 pseudovirions using a starting antibody concentration of 200 nM (30 μg/ml). NA, not applicable.